Francisco Marín

TL;DR: The coronavirus disease 2019 (COVID‐19) shows high morbidity and mortality, particularly in patients with concomitant cardiovascular diseases, and some of these patients are under oral anticoagulation (OAC) at admission, but to date there are no data on the clinical profile, prognosis and risk factors of such patients during hospitalization for CO VID‐19.

TL;DR: In anticoagulated patients with AF followed‐up over a long‐term period, the novel ABC‐stroke score does not offer significantly better predictive performance compared with the CHA 2 DS 2‐VASc score.

TL;DR: In this article, a large-scale clinical trial was conducted to test the hypothesis that the new CHADS2 and Framingham point-based risk stratification scores could be related to plasma vWf and soluble E-selectin (an index of endothelial activation) levels in a large cohort of AF patients.

TL;DR: By adding consecutive biomarkers, the predictive performance of CHA2DS2-VASc for ischemic stroke was not increased, whereas the predictive ability of HAS-BLED for major bleeding was only slightly enhanced, and the net benefit and clinical usefulness of the biomarker-based models were marginal in comparison to the original scores based on clinical factors.

TL;DR: FXIII Val34Leu polymorphism was independently associated with IL6 levels in AF, and may potentially influence the prothrombotic state in these patients by modulating the inflammatory state.